Cardinal Health's major customers
CVS Health accounted for 28% of Cardinal Health's revenue in FY 2026, about the same as 30% a year earlier. 10 listed suppliers report Cardinal Health as a customer worth 10% or more of their revenue, led by Gilead Sciences at 29%.
Get an email when Cardinal Health's customer concentration changes
When a new annual report adds a 10% customer, drops one, or moves a share by 5 points or more, you get the change and the filing link. Up to 10 companies per address, no account, unsubscribe with one click.
Major customers of Cardinal Health
Customers that Cardinal Health named in its annual report as 10% or more of revenue. A missing year means the customer was below that line or not named.
| Customer | Share of revenue | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| CVS HealthCVS | 28% | from 30% | 5 years | FY 2026 · filed 11 Aug 2026 |
Formerly disclosed
| Customer | Share of revenue | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| CVS Caremark | 25% | last FY 2023 | 5 years | FY 2023 · filed 15 Aug 2023 |
| Optum Rx | 17% | last FY 2024 | 6 years | FY 2024 · filed 11 Aug 2026 |
Suppliers that depend on Cardinal Health
Listed companies whose annual report names Cardinal Health as a customer worth 10% or more of their revenue. If Cardinal Health cuts orders or switches supplier, these are the companies that feel it.
| Supplier | Its revenue from this company | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| Gilead SciencesGILD | 29% | from 29% | 10 years | FY 2025 · filed 24 Feb 2026 |
| Bristol Myers SquibbBMY | 22% | from 22% | 7 years | FY 2025 · filed 11 Feb 2026 |
| ADC TherapeuticsADCT | 22% | from 24% | 4 years | FY 2025 · filed 10 Mar 2026 |
| ArdelyxARDX | 21% | ▲ from 14% | 4 years | FY 2025 · filed 19 Feb 2026 |
| Amphastar PharmaceuticalsAMPH | 19% | from 19% | 14 years | FY 2025 · filed 26 Feb 2026 |
| AlkermesALKS | 17% | from 19% | 7 years | FY 2025 · filed 25 Feb 2026 |
| Bausch Health CompaniesBHC | 14% | from 14% | 15 years | FY 2025 · filed 19 Feb 2026 |
| PfizerPFE | 13% | from 14% | 8 years | FY 2025 · filed 26 Feb 2026 |
| ModernaMRNA | 11% | new | 1 year | FY 2025 · filed 20 Feb 2026 |
| Bausch & LombBLCO | 10% | from 10% | 2 years | FY 2025 · filed 18 Feb 2026 |
Formerly disclosed
| Supplier | Its revenue from this company | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| Ani PharmaceuticalsANIP | 23% | last FY 2019 | 1 year | FY 2019 · filed 15 Mar 2022 |
| Rigel PharmaceuticalsRIGL | 13% | last FY 2024 | 3 years | FY 2024 · filed 3 Mar 2026 |
| DexcomDXCM | 10% | last FY 2022 | 2 years | FY 2022 · filed 9 Feb 2023 |
| Akebia TherapeuticsAKBA | 10% | last FY 2023 | 2 years | FY 2023 · filed 26 Feb 2026 |
| ViatrisVTRS | 5% | last FY 2023 | 5 years | FY 2023 · filed 26 Feb 2026 |
About this data
US-listed companies must disclose revenue from any single customer that reaches 10% of their total (ASC 280). ShadowGraph reads these disclosures from the XBRL data of every 10-K and 20-F we scan, keeps one value per fiscal year (restatements replace earlier values) and links each number to its filing. Companies that describe a customer only as "Customer A" are not listed by name. Figures are as reported; nothing here is investment advice.
All companies · Latest dependency shifts · Bulk data and API